Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

This study is looking for adults aged 18 or older who have recently been diagnosed with Acute Myeloid Leukemia (AML). Your doctors will need to check your genes to make sure your AML fits into the ‘intermediate’ or ‘adverse-risk’ categories for this study. This might include AML that has developed from a previous condition or has occurred after other cancer treatments.

You would also need to be well enough to have strong chemotherapy, which your doctor will assess. This includes having good kidney and liver function. If you've had some very short, temporary treatment (like hydroxyurea for up to 14 days) to control your white blood cell count before your diagnosis, you might still be eligible. If you're a woman who could become pregnant, you would need to have a negative pregnancy test and agree to use contraception during the study. You can't have had previous chemotherapy for AML, except in very specific situations.

Your doctor will discuss all these points with you and do specific tests to see if you are a good fit for this study. They will also check your general health, for example, your ability to carry out everyday activities.

If you decide to take part in this study, you would first undergo several health checks and tests to confirm you are suitable. Once confirmed, you would be randomly assigned to receive either the new CPX-351 treatment or the standard chemotherapy. This is like flipping a coin, so neither you nor your doctor can choose which treatment you get. Both treatments involve receiving medicines, usually through a drip.

You would have your treatment in cycles, with periods of rest in between. During the treatment, you’ll have regular hospital visits, blood tests, and other health checks to see how you are responding to the treatment and to monitor for any side effects. You will be closely supported by your medical team throughout. The total duration of your participation would depend on how your treatment progresses and includes follow-up appointments after your main treatment period.